NCT00002365 is a Phase 1 clinical trial of LXR015-1 in HIV Infections, sponsored by LXR Biotechnology.

Who is sponsoring NCT00002365?

NCT00002365 is sponsored by LXR Biotechnology.

What drugs are being tested in NCT00002365?

Interventions in NCT00002365: LXR015-1.

What condition does NCT00002365 study?

NCT00002365 studies HIV Infections.

Is NCT00002365 still recruiting?

NCT00002365 is currently completed. Last updated 23 June 2005.

Last reviewed 2005-06-23 · How we verify

NCT00002365

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized, Parallel, Open-Label Phase I Study of LXR015-1 in HIV-Infected Patients

Completed Phase 1 Last updated 23 June 2005

What this trial tests

Phase 1 trial testing LXR015-1 in HIV Infections in 30 participants. Completed.

Quick facts

Lead sponsor	LXR Biotechnology
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Masking	none
Primary purpose	treatment
Enrollment	30
Sites	1 location across United States

Drugs / interventions tested

LXR015-1 — full drug profile →

Conditions studied

HIV Infections — all drugs for HIV Infections →

Sponsor

LXR Biotechnology — full company profile →

Who can join

18 and older, any sex, with HIV Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine and compare the safety and tolerability of 3 doses of LXR015-1 in HIV-infected patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for HIV Infections

Currently open trials in the same condition.

NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00002365 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by LXR Biotechnology
Last refreshed: 23 June 2005

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00002365.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing